描述：
CST公司在大肠杆菌中生产重组人蛋白IL-8 (hIL-8) Ser28-Ser99 (Accession #NM_000584)。重组的hIL-8蛋白在N-末端没有Met标签，分子量据推算为8,386Da。DTT-还原和未还原的蛋白迁移时是作为一个8kDa 的多肽而转移，重组hIL-8蛋白的N-末端SAKEL的序列通过测序确定。6 μg 还原 (+) 和 非还原的(-) hIL-8通过SDS-PAGE检测，纯度大于98%，所有批次的纯度均高于98%。重组蛋白hIL-8的生物活性是通过对人中性粒细胞原代细胞升高CD11b表达实验确定的。每个的批次的ED50在1-5ng/ml之间。内毒素含量:<0.01 ng /1 μg hIL-8。
有载体:SC: 每微克hIL-8蛋白溶解在包含 20 μg BSA的PBS（pH 7.2）溶液中，终浓度为0.25 mg/ml ，并通过 0.22 μm 滤膜冻干。LC:每微克hIL-8蛋白溶解在包含 20 μg BSA的PBS（pH 7.2）溶液中，终浓度为0.33 mg/ml ，并通过 0.22 μm 滤膜冻干。
有载体:SC: 每微克hIL-8蛋白溶解在PBS（pH 7.2）溶液中，终浓度为0.25 mg/ml ，并通过 0.22 μm 滤膜冻干。LC:每微克hIL-8蛋白溶解在PBS（pH 7.2）溶液中，终浓度为0.33 mg/ml ，并通过 0.22 μm 滤膜冻干。
IL-8，是CXC趋化因子的典型成员，最为知名的是其对中性粒细胞的调节作用，特别是作为一个趋化物和激活细胞脱粒和呼吸爆发的作用(1,2,3)。IL-8能够被一系列细胞类型产生，包括单核细胞、T细胞、中性粒细胞、成纤维细胞、内皮细胞和其它细胞(1)。除了它对中性粒细胞的作用, IL-8促进血管生成，抑制内皮细胞凋亡，并促进黑色素瘤细胞以自分泌方式的增殖(1)。因此, IL-8 可能对一些肿瘤的发展有作用(1,2)。IL-8有两个不同的受体, CXCR1和CXCR2; 它们都是G蛋白偶联受体(1)。配体的结合诱导了Ca2+的游离并激活PI3K, PKC, Rho 和Rac 信号通路(1,3)。
原厂资料：
Source / Purification
Recombinant human IL-8 (hIL-8) Ser28-Ser99 (Accession #NM_000584) was produced in E.coli at Cell Signaling Technology.
Molecular Characterization
Recombinant hIL-8 does not have a Met on the amino terminus and has a calculated MW of 8,386. DTT-reduced and non-reduced protein migrate as 8 kDa polypeptides. The expected amino-terminal SAKEL of recombinant hIL-8 was verified by amino acid sequencing.
Purity
>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant hIL-8. All lots are greater than 98% pure.
Bioactivity
The bioactivity of recombinant hIL-8 was determined by upregulation of CD11b expression on primary human neutrophils. The ED50 of each lot is between 1-5 ng/ml.
Endotoxin
Less than 0.01 ng endotoxin/1 μg hIL-8.
Formulation
With carrier:SC: A 0.22 μm filtered solution of 0.25 mg/ml hIL-8 in PBS, pH 7.2 containing 20 μg BSA per 1 μg hIL-8.LC: A 0.22 μm filtered solution of 0.33 mg/ml hIL-8 in PBS, pH 7.2 containing 20 μg BSA per 1 μg hIL-8.Carrier free:SF: A 0.22 μm filtered solution of 0.25 mg/ml hIL-8 in PBS, pH 7.2.LF: A 0.22 μm filtered solution of 0.33 mg/ml hIL-8 in PBS, pH 7.2.
Background
The prototypical CXC chemokine, IL-8, is best known for effects on neutrophils, specifically its ability to act as a chemoattractant and activate degranulation and respiratory burst (1,2,3).
IL-8 is produced by a number of cell types including monocytes, T cells, neutrophils, fibroblasts, endothelial cells, and others (1). In addition to its effects on neutrophils, IL-8 promotes angiogenesis, inhibits endothelial cell apoptosis, and promotes the proliferation of melanoma cells in an autocrine fashion (1). As a result, IL-8 may be a contributing factor to the development of certain cancers (1,2). There are two distinct receptors for IL-8, CXCR1 and CXCR2; both are G protein-coupled receptors (1). Ligand binding induces Ca2+ mobilization and activates the PI3K, PKC, Rho, and Rac pathways (1,3).
京公网安备11010802025653 版权所有：北京逸优科技有限公司
